Methods of inhibiting tumor growth and angiogenesis with anastellin
First Claim
Patent Images
1. A substantially pure composition comprising anastellin (SEQ ID NO:
- 1) and fibrinogen.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides a substantially pure composition of anastellin (SEQ ID NO: 1) and fibrinogen as well as a substantially pure composition of superfibronectin and superfibrinogen. The invention also provides methods of inhibiting angiogenesis, tumor growth and metastasis by administering anastellin (SEQ ID NO: 1) alone or in combination with fibrinogen.
-
Citations
14 Claims
-
1. A substantially pure composition comprising anastellin (SEQ ID NO:
- 1) and fibrinogen.
-
2. A substantially pure composition comprising superfibrinogen (sFBG) and superfibronectin (sFN).
-
3. A method of preparing superfibrinogen (sFBG) comprising contacting fibrinogen with anastellin (SEQ ID NO:
- 1) under conditions that allow formation of super-fibrinogen (sFBG).
-
4. A method of inhibiting angiogenesis comprising administering anastellin (SEQ ID NO:
- 1) in an amount effective to inhibit angiogenesis, wherein said amount is 0.5 mg or greater.
-
5. A method of inhibiting tumor growth comprising administering anastellin (SEQ ID NO:
- 1) in an amount effective to inhibit tumor growth, wherein said amount is 0.5 mg or greater.
- 6. A method of inhibiting angiogenesis comprising administering fibrinogen and a fibrinogen polymerizing agent in an amount effective to inhibit angiogenesis.
- 9. A method of inhibiting tumor growth comprising administering fibrinogen and a fibrinogen polymerizing agent in an amount effective to inhibit tumor growth.
- 12. A method of inhibiting metastasis comprising administering fibrinogen and a fibrinogen polymerizing agent in an amount effective to inhibit metastasis.
Specification